Brimotale Plus Eye Drop contains Brimonidine 0.2% w/v, a selective alpha-2 adrenergic agonist used to lower elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Its proven formulation ensures effective and well-tolerated long-term therapy.
The eye drop works by reducing aqueous humor production and increasing uveoscleral outflow, helping to maintain controlled eye pressure and protect the optic nerve, thereby supporting long-term visual health.
From a franchise perspective, Brimotale Plus Eye Drop is a high-demand anti-glaucoma ophthalmic product, widely prescribed in eye hospitals, ophthalmology clinics, and specialty glaucoma centers, ensuring consistent prescriptions and repeat sales.
Adding Brimotale Plus Eye Drop to your portfolio strengthens the ophthalmic anti-glaucoma segment, offering long-term growth, strong prescriber confidence, and enhanced portfolio credibility for PCD pharma franchise partners.
Common side effects may include eye redness, burning or stinging sensation, itching, dryness, or blurred vision. Some patients may experience dry mouth, fatigue, headache, or drowsiness. Rarely, allergic conjunctivitis or hypersensitivity reactions may occur.
Brimotale Plus Eye Drop is indicated for the treatment of open-angle glaucoma and ocular hypertension. It is used to reduce elevated intraocular pressure and prevent optic nerve damage under the supervision of an ophthalmologist.
Use Brimotale Plus Eye Drop strictly as directed by an ophthalmologist. Avoid touching the dropper tip to the eye to prevent contamination. Use with caution in patients with cardiovascular disease, depression, or those taking antihypertensive medications. Discontinue use and consult a doctor if severe eye irritation or systemic symptoms occur.
Store in a cool, dry place below 25°C. Protect from direct sunlight, keep the bottle tightly closed, and out of reach of children. Do not use beyond the expiry date.